BRPI0710964A2 - método de tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular; composição farmacêutica; uso de composto na fabricação de um medicamento para o tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular - Google Patents

método de tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular; composição farmacêutica; uso de composto na fabricação de um medicamento para o tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular Download PDF

Info

Publication number
BRPI0710964A2
BRPI0710964A2 BRPI0710964-4A BRPI0710964A BRPI0710964A2 BR PI0710964 A2 BRPI0710964 A2 BR PI0710964A2 BR PI0710964 A BRPI0710964 A BR PI0710964A BR PI0710964 A2 BRPI0710964 A2 BR PI0710964A2
Authority
BR
Brazil
Prior art keywords
muscle
injury
loss
atrophy
degeneration
Prior art date
Application number
BRPI0710964-4A
Other languages
English (en)
Inventor
Phillip Vlasuk Geoge
Leroy Crandall David
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of BRPI0710964A2 publication Critical patent/BRPI0710964A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

MéTODO DE TRATAMENTO DE LESãO MUSCULAR, PERDA MUSCULAR, DEGENERAçãO MUSCULAR, ATROFIA MUSCULAR OU TAXA REDUZIDA DE REPARO MUSCULAR; COMPOSIçãO FARMACêUTICA; E USO DE COMPOSTO NA FABRICAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE LESãO MUSCULAR, PERDA MUSCULAR, DEGENERAçãO MUSCULAR, ATROFIA MUSCULAR OU TAXA REDUZIDA DE REPARO MUSCULAR. Esta invenção descreve novos métodos de tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxas reduzidas de reparo muscular associadas a várias condições, como distrofia muscular, mediante uso de inibidores de PAI-1 de pequena molécula.
BRPI0710964-4A 2006-02-27 2007-02-26 método de tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular; composição farmacêutica; uso de composto na fabricação de um medicamento para o tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular BRPI0710964A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77752106P 2006-02-27 2006-02-27
US777,521 2006-02-27
PCT/US2007/005069 WO2007098278A2 (en) 2006-02-27 2007-02-26 Inhibitors of pai-1 for treatment of muscular conditions

Publications (1)

Publication Number Publication Date
BRPI0710964A2 true BRPI0710964A2 (pt) 2012-02-28

Family

ID=38438022

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710964-4A BRPI0710964A2 (pt) 2006-02-27 2007-02-26 método de tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular; composição farmacêutica; uso de composto na fabricação de um medicamento para o tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular

Country Status (20)

Country Link
US (1) US20070203220A1 (pt)
EP (1) EP2010171A2 (pt)
JP (1) JP2009528290A (pt)
KR (1) KR20080108407A (pt)
CN (1) CN101384256A (pt)
AR (1) AR059629A1 (pt)
AU (1) AU2007217363A1 (pt)
BR (1) BRPI0710964A2 (pt)
CA (1) CA2643731A1 (pt)
CR (1) CR10253A (pt)
EC (1) ECSP088699A (pt)
GT (1) GT200800167A (pt)
IL (1) IL192975A0 (pt)
MX (1) MX2008011015A (pt)
NO (1) NO20083438L (pt)
PE (1) PE20071017A1 (pt)
RU (1) RU2008128475A (pt)
TW (1) TW200744585A (pt)
WO (1) WO2007098278A2 (pt)
ZA (1) ZA200807357B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176477A1 (en) * 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
GB0812192D0 (en) * 2008-07-03 2008-08-13 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN103724357B (zh) * 2012-10-11 2016-06-08 中国药科大学 一种3,4-二氢吡喃并[3,2-b]吲哚-2-酮类化合物的合成方法
WO2017073060A1 (ja) * 2015-10-29 2017-05-04 国立大学法人東北大学 コラーゲン産生抑制剤
US12011455B2 (en) * 2016-03-17 2024-06-18 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
EP4122489A4 (en) * 2020-03-24 2023-04-12 Talengen International Limited METHODS AND MEDICATIONS FOR PROMOTING THE BREAKDOWN OF MISFOLDED PROTEIN AND AGGREGATE THEREOF
EP4140498A4 (en) * 2020-05-11 2023-11-01 Talengen International Limited Method and drug for treating spinal muscular atrophy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) * 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TW591020B (en) * 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) * 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
CA2509170A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1569900B1 (en) * 2002-12-10 2006-06-28 Wyeth Substituted 3-carbonyl-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60324183D1 (en) * 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
CA2509222A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) * 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US20050215626A1 (en) * 2003-09-25 2005-09-29 Wyeth Substituted benzofuran oximes
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
AU2005277137A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
WO2006023865A1 (en) * 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
CN101044127A (zh) * 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
BRPI0614340A2 (pt) * 2005-08-17 2011-04-12 Wyeth Corp indóis substituìdos e métodos de seu uso

Also Published As

Publication number Publication date
AU2007217363A1 (en) 2007-08-30
EP2010171A2 (en) 2009-01-07
KR20080108407A (ko) 2008-12-15
WO2007098278A3 (en) 2008-03-20
JP2009528290A (ja) 2009-08-06
NO20083438L (no) 2008-10-31
TW200744585A (en) 2007-12-16
RU2008128475A (ru) 2010-04-10
ZA200807357B (en) 2009-08-26
AR059629A1 (es) 2008-04-16
US20070203220A1 (en) 2007-08-30
CR10253A (es) 2008-11-18
IL192975A0 (en) 2009-08-03
ECSP088699A (es) 2008-09-29
WO2007098278A2 (en) 2007-08-30
GT200800167A (es) 2009-01-15
MX2008011015A (es) 2008-11-14
PE20071017A1 (es) 2007-11-12
CA2643731A1 (en) 2007-08-30
CN101384256A (zh) 2009-03-11

Similar Documents

Publication Publication Date Title
BRPI0710964A2 (pt) método de tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular; composição farmacêutica; uso de composto na fabricação de um medicamento para o tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
WO2008032072A8 (en) 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
WO2008030883A3 (en) Treatment of cancer
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
WO2007011962A3 (en) Treatment of cancer
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
WO2007143607A3 (en) Method of treating atrophic vaginitis
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BRPI0816814A2 (pt) composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A E 5A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.